| Title |
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
|
|---|---|
| Published in |
Psychopharmacology, April 2009
|
| DOI | 10.1007/s00213-009-1521-8 |
| Pubmed ID | |
| Authors |
Atheir I. Abbas, Peter B. Hedlund, Xi-Ping Huang, Thuy B. Tran, Herbert Y. Meltzer, Bryan L. Roth |
| Abstract |
Amisulpride is approved for clinical use in treating schizophrenia in a number of European countries and also for treating dysthymia, a mild form of depression, in Italy. Amisulpride has also been demonstrated to be an antidepressant for patients with major depression in many clinical trials. In part because of the selective D(2)/D(3) receptor antagonist properties of amisulpride, it has long been widely assumed that dopaminergic modulation is the proximal event responsible for mediating its antidepressant and antipsychotic properties. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 171 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Poland | 2 | 1% |
| United States | 1 | <1% |
| India | 1 | <1% |
| Unknown | 167 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 26 | 15% |
| Researcher | 26 | 15% |
| Student > Master | 22 | 13% |
| Student > Bachelor | 21 | 12% |
| Professor > Associate Professor | 12 | 7% |
| Other | 33 | 19% |
| Unknown | 31 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 22% |
| Agricultural and Biological Sciences | 21 | 12% |
| Neuroscience | 19 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 10% |
| Chemistry | 13 | 8% |
| Other | 24 | 14% |
| Unknown | 39 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 43. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2024.
All research outputs
#859,441
of 23,476,369 outputs
Outputs from Psychopharmacology
#214
of 5,409 outputs
Outputs of similar age
#2,059
of 95,497 outputs
Outputs of similar age from Psychopharmacology
#1
of 34 outputs
Altmetric has tracked 23,476,369 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,409 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,497 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.